Market Overview:
The global dacarbazine (CAS 4342-03-4) market is expected to register a CAGR of xx.xx% during the forecast period, 2018–2030. The hospital pharmacies segment is projected to account for the highest market share in terms of value, followed by retail pharmacies and online pharmacies segments respectively. North America dominates the global dacarbazine (CAS 4342-03-4) market in terms of value and volume, followed by Europe and Asia Pacific respectively.
Product Definition:
Dacarbazine (CAS 4342-03-4) is an anticancer agent that belongs to the group of alkylating agents. It is used for the treatment of metastatic malignant melanoma and Hodgkin's lymphoma.
100mg/Bottle:
100mg/Bottle, it's usage and growth factor in Dacarbazine (CAS 4342-03-4) market? 100 mg/bottle is the standard dosage for cancer chemotherapy. It is administered intravenously as a single dose or divided doses every two to three days. The medication has been used extensively in the treatment of brain tumors and can be used with other therapies such as radiation therapy, surgery, and immunotherapy.
200mg/Bottle:
200mg/Bottle is a generic medicine used for the treatment of cancer. It is manufactured by different companies and sold at varied prices in different countries. 200 mg/ Bottle contains 200 mg of Dacarbazine, which is one of the most effective chemotherapeutic agents used in oncology treatment.
Dacarbazine (CAS 4342-03-4) has been approved by the U.
Application Insights:
The hospital pharmacies segment held the largest share of over 60.0% in 2017. The segment is expected to witness significant growth owing to rising usage of dacarbazine for chemotherapy and other cancer treatments in hospitals and healthcare centers. Furthermore, increasing number of research studies supporting the use of dacarbazine as a chemotherapeutic agent in the treatment of various cancers including pancreatic cancer, lung cancer, breast carcinoma and others is expected to boost demand over the forecast period.
Dacarbazine-based drugs are used for treating skin tumors such as malignant melanoma or keratoctanthiasis (a common name for skin tumor). It has been found effective against cutaneous metastases from different primary sites such as breast carcinoma or liver carcinoma due to its high mutational selectivity property which makes it an ideal drug candidate for oncology indications across various regions globally.
Regional Analysis:
North America dominated the global market in 2017. This is attributed to the presence of a large number of key players, high adoption rate for new drugs, and availability of approved dacarbazine tablets for oral administration. Moreover, increasing incidence rates of cancer has led to an increase in demand for oncology products such as dacarbazine which are used as first line therapy against malignant tumors.
Asia Pacific is expected to be one of the fastest growing regions during the forecast period owing to rising healthcare expenditure and improving access due to increased foreign investments coupled with regulatory reforms by governments aimed at promoting competition among various pharmaceutical companies operating in this region. Furthermore, increasing awareness about advanced treatment options leading towards better patient care outcomes is anticipated to fuel growth over the forecast period.
Growth Factors:
- Increasing incidence of melanoma: The incidence of melanoma is increasing globally due to the changing lifestyle and rising awareness about the disease. This is expected to drive the demand for dacarbazine in the coming years.
- Growing use of targeted therapies: The use of targeted therapies such as dacarbazine is growing rapidly due to their better efficacy and safety profile as compared to traditional chemotherapy regimens. This is likely to boost the demand for dacarbazine in the near future.
- Rising prevalence of cancer: The global prevalence of cancer is rising at an alarming rate, which is expected to create a significant demand for anticancer drugs such as dacarbazine in the coming years.
- Technological advancements: The development of novel formulations and delivery technologies for dacarbazine will help improve its therapeutic efficacy and patient compliance, thereby driving its market growth over the forecast period.. 5) Increasing healthcare expenditure: Rising healthcare expenditure worldwide will lead to an increase in spending on drugs such as Dacarbazine, thereby propelling market growth during forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Dacarbazine (CAS 4342-03-4) Market Research Report
By Type
100mg/Bottle, 200mg/Bottle, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Lingnan Pharma, Ruiying Xianfeng Pharma, Sino-Pharma Yixin, Nanjing Pharma, Pude Pharma, TEVA, DBL Pharma, Cytomed, Salius Pharma, Celon Labs
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Dacarbazine (CAS 4342-03-4) Market Report Segments:
The global Dacarbazine (CAS 4342-03-4) market is segmented on the basis of:
Types
100mg/Bottle, 200mg/Bottle, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Lingnan Pharma
- Ruiying Xianfeng Pharma
- Sino-Pharma Yixin
- Nanjing Pharma
- Pude Pharma
- TEVA
- DBL Pharma
- Cytomed
- Salius Pharma
- Celon Labs
Highlights of The Dacarbazine (CAS 4342-03-4) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 100mg/Bottle
- 200mg/Bottle
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dacarbazine (CAS 4342-03-4) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dacarbazine is a chemotherapy agent that is used to treat cancer. It works by killing cancer cells.
Some of the key players operating in the dacarbazine (cas 4342-03-4) market are Lingnan Pharma, Ruiying Xianfeng Pharma, Sino-Pharma Yixin, Nanjing Pharma, Pude Pharma, TEVA, DBL Pharma, Cytomed, Salius Pharma, Celon Labs.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Dacarbazine (CAS 4342-03-4) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Dacarbazine (CAS 4342-03-4) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Dacarbazine (CAS 4342-03-4) Market - Supply Chain
4.5. Global Dacarbazine (CAS 4342-03-4) Market Forecast
4.5.1. Dacarbazine (CAS 4342-03-4) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Dacarbazine (CAS 4342-03-4) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Dacarbazine (CAS 4342-03-4) Market Absolute $ Opportunity
5. Global Dacarbazine (CAS 4342-03-4) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Type
5.3.1. 100mg/Bottle
5.3.2. 200mg/Bottle
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Dacarbazine (CAS 4342-03-4) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Dacarbazine (CAS 4342-03-4) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Dacarbazine (CAS 4342-03-4) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Dacarbazine (CAS 4342-03-4) Demand Share Forecast, 2019-2026
9. North America Dacarbazine (CAS 4342-03-4) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Type
9.7.1. 100mg/Bottle
9.7.2. 200mg/Bottle
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Dacarbazine (CAS 4342-03-4) Demand Share Forecast, 2019-2026
10. Latin America Dacarbazine (CAS 4342-03-4) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Type
10.7.1. 100mg/Bottle
10.7.2. 200mg/Bottle
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Dacarbazine (CAS 4342-03-4) Demand Share Forecast, 2019-2026
11. Europe Dacarbazine (CAS 4342-03-4) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Type
11.7.1. 100mg/Bottle
11.7.2. 200mg/Bottle
11.7.3. Others
11.8. BasisPoint Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Dacarbazine (CAS 4342-03-4) Demand Share, 2019-2026
12. Asia Pacific Dacarbazine (CAS 4342-03-4) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Type
12.7.1. 100mg/Bottle
12.7.2. 200mg/Bottle
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Dacarbazine (CAS 4342-03-4) Demand Share, 2019-2026
13. Middle East & Africa Dacarbazine (CAS 4342-03-4) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Dacarbazine (CAS 4342-03-4) Market Size and Volume Forecast by Type
13.7.1. 100mg/Bottle
13.7.2. 200mg/Bottle
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Dacarbazine (CAS 4342-03-4) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Dacarbazine (CAS 4342-03-4) Market: Market Share Analysis
14.2. Dacarbazine (CAS 4342-03-4) Distributors and Customers
14.3. Dacarbazine (CAS 4342-03-4) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Lingnan Pharma
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Ruiying Xianfeng Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sino-Pharma Yixin
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Nanjing Pharma
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Pude Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. TEVA
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. DBL Pharma
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Cytomed
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Salius Pharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Celon Labs
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook